Descripción del proyecto
Una tecnología que mejora la vida de los pacientes con síndrome de fatiga crónica
El síndrome de fatiga crónica (SFC) es una afección grave y compleja que afecta a un elevado porcentaje de la población mundial. A menudo, su desencadenante es una infección que provoca disbiosis. A pesar de su causa común, el SFC no suele diagnosticarse muchas veces. Sin embargo, cuando se diagnostica, no se trata de forma eficaz por falta de métodos. El objetivo del proyecto financiado con fondos europeos Help4ME es colmar esta brecha en la investigación. El equipo del proyecto trabaja en el desarrollo de un innovador probiótico eficaz para tratar la disbiosis. Este nuevo producto basado en la combinación única de cinco cepas de lactobacilos y con eficacia demostrada promete mejorar sustancialmente la calidad de vida de los enfermos de SFC.
Objetivo
Let’s imagine being tired to the point where any activity causes weeks of weakness and pain. Common noises and daylight become an unbearable torture and a “brain fog” doesn’t let you think clearly. In spite of the tiredness, you wake up without being refreshed, if you can fall asleep at all. Days pass as well as doctors check-ups, and no one is able to tell you what is wrong. Finally, after few years of trying to pull yourself up, the answer is Chronic Fatigue Syndrome (CFS). Happy of the fact of being diagnosed, you quickly learn that it means that there are no measures able to cure you and chances of full recovery are only 5%.
Indeed, the reality of CFS patients’ life is tough and contrary to many beliefs it is not a rare disease. The world count of diagnosed CFS is estimated for up to 24 million cases and considered to be only 10% of the whole CFS population. Although frequently triggered by infection, cause of CFS is not yet known. Researches look for its source in the guts, which are inhabited by billions of microorganisms and form a complex ecosystem with profound impact on the whole body. Imbalance of gut microflora, damaged gut barrier functions and dysfunctional immune responses are known in CFS and shared with another disease - Irritable Bowel Syndrome (IBS), which frequently accompany CFS.
GutMagnific™ is an evidence-based probiotic scientifically designed and shown to be effective in correcting the gut microflora disbalance – a source of CFS and IBS symptoms. The novelty of the product lies in the unique combination of 5 lactobacilli strains with evidence-based efficacy and shows a life-changing promise to severely underserved population of CFS patients.
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
226 50 LUND
Suecia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.